[1] GRATWOHL A, BALDOMERO H, SCHWENDENER A, et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplant. 2009;43(4):275-291.
[2] PASSWEG JR, BALDOMERO H, BADER P, et al. Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2018;53(9): 1139-1148.
[3] ANDERLINI P, WU J, GERSTEN I, et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015;2(9):e367-e375.
[4] DUFOUR C, VEYS P, CARRARO E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171(4): 585-594.
[5] GIAMMARCO S, PEFFAULT DE LATOUR R, SICA S, et al. Transplant outcome for patients with acquired aplastic anemia over the age of 40: has the outcome improved? Blood. 2018; 131(17):1989-1992.
[6] 王振龙,于洁.联合免疫抑制和无关供者造血干细胞移植治疗儿童重型再生障碍性贫血研究进展[J].儿科药学杂志,2014,20(12): 57-61.
[7] KILLICK SB, BOWN N, CAVENAGH J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.
[8] 付蓉,刘春燕.再生障碍性贫血诊断与治疗中国专家共识(2017版)解读[J].临床血液学杂志,2017,30(6):821-825.
[9] BACIGALUPO A. Alternative donor transplants for severe aplastic anemia. Hematology Am Soc Hematol Educ Program. 2018;2018(1):467-473.
[10] 何平,王畅,谭业辉.不同类型供者造血干细胞移植治疗儿童再生障碍性贫血的进展[J].中国免疫学杂志,2017,33(3):477-480.
[11] SCHEINBERG P, NUNEZ O, YOUNG NS. Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol. 2006;133(6):622-627.
[12] DEEG HJ, AMYLON ID, HARRIS RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7(4):208-215.
[13] KOJIMA S, MATSUYAMA T, KATO S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100(3):799-803.
[14] BACIGALUPO A, LOCATELLI F, LANINO E, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36(11):947-950.
[15] KANG HJ, SHIN HY, PARK JE, et al. Successful engraftment with fludarabine, cyclophosphamide, and thymoglobulin conditioning regimen in unrelated transplantation for severe aplastic anemia: A phase II prospective multicenter study. Biol Blood Marrow Transplant. 2010;16(11):1582-1588.
[16] ALJURF M, AL-ZAHRANI H, VAN LINT MT, et al. Standard treatment of acquired SAA in adult patients 18-40 years old with an HLA-identical sibling donor. Bone Marrow Transplant. 2013;48(2):178-179.
[17] BACIGALUPO A, SOCIE' G, LANINO E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95(6):976-982.
[18] KILLICK SB, BOWN N, CAVENAGH J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187-207.
[19] KOSAKA Y, YAGASAKI H, SANO K, et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood. 2008;111(3):1054-1059.
[20] DUFOUR C, VEYS P, CARRARO E, et al. Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT. Br J Haematol. 2015;171(4):585-594.
[21] SCHEINBERG P, YOUNG NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-1196.
[22] TOWNSLEY DM, SCHEINBERG P, WINKLER T, et al. Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia. N Engl J Med. 2017;376(16):1540-1550.
[23] DESMOND R, TOWNSLEY DM, DUMITRIU B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014;123(12):1818-1825.
[24] HORAN J, WANG T, HAAGENSON M, et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood. 2012;120 (14):2918-2924.
[25] DEEG HJ, O'DONNELL M, TOLAR J, et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood. 2006;108(5): 1485-1491.
[26] BACIGALUPO A, SOCIE' G, LANINO E, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica. 2010;95(6):976-982.
[27] KHOURI IF, SALIBA RM, GIRALT SA, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98(13):3595-3599.
[28] OKUDA S, TERASAKO K, OSHIMA K, et al. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function. Am J Hematol. 2009; 84(3):167-169.
[29] KOH LP, KOH MB, NG HY, et al. Allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia following nonmyeloablative conditioning using 200-cGy total body irradiation and fludarabine. Biol Blood Marrow Transplant. 2006;12(8):887-890.
[30] GEORGE B, MATHEWS V, VISWABANDYA A, et al. Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia. Bone Marrow Transplant. 2007;40(1):13-18.
[31] RESNICK IB, AKER M, SHAPIRA MY, et al. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen. Br J Haematol. 2006;133(6):649-654.
[32] BACIGALUPO A, SOCIÉ G, HAMLADJI RM, et al. Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis. Haematologica. 2015;100(5):696-702.
[33] KEKRE N, ZHANG Y, ZHANG MJ, et al. Effect of antithymocyte globulin source on outcomes of bone marrow transplantation for severe aplastic anemia. Haematologica. 2017;102(7):1291-1298.
[34] VAN ESSER JW, VAN DER HOLT B, MEIJER E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood. 2001;98(4):972-978.
[35] DOMINIETTO A, TEDONE E, SORACCO M, et al. In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant. 2012;47(1):101-106.
[36] MARSH JC, GUPTA V, LIM Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood. 2011; 118(8):2351-2357.
[37] MARSH JC, PEARCE RM, KOH MB, et al. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49(1):42-48.
[38] SCHREZENMEIER H, PASSWEG JR, MARSH JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397-1400.
[39] BACIGALUPO A, SOCIÉ G, SCHREZENMEIER H, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012;97(8):1142-1148.
[40] EAPEN M, LE RADEMACHER J, ANTIN JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011;118(9): 2618-2621.
[41] PEFFAULT DE LATOUR R, CHEVRET S, JUBERT C, et al. Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study. Blood. 2018;132(7):750-754.
[42] PEFFAULT DE LATOUR R, ROCHA V, SOCIÉ G. Cord blood transplantation in aplastic anemia. Bone Marrow Transplant. 2013;48(2):201-202.
[43] 黄宁.非血缘异基因脐血移植治疗重型再生障碍性贫血14例[A]//第十一届全国红细胞疾病学术会议暨学习班论文汇编[C].青岛:第十一届全国红细胞疾病学术会议暨学习班,2007.
[44] 朱兴虎,张丽,魏旭东,等.非血缘HLA不相合脐血移植治疗儿童重型再生障碍性贫血二例[J].中华儿科杂志,2006,44(2):143-144.
[45] 林东军.非血缘脐血移植治疗恶性血液病的研究进展[J].实用医学杂志,2016,32(1):14-16.
[46] 邱大发.脐带血在血液病治疗中的应用概况[J].深圳中西医结合杂志,2016,26(3):190-192.
[47] 邵珊,蔡宇,万理萍,等.免疫抑制联合脐血输注治疗重型再生障碍性贫血[J].内科理论与实践,2018,13(2):81-86.
[48] ESTEVES I, BONFIM C, PASQUINI R, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015;50(5):685-689.
[49] IM HJ, KOH KN, SEO JJ. Haploidentical hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia. Korean J Pediatr. 2015;58(6):199-205.
[50] CLAY J, KULASEKARARAJ AG, POTTER V, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20(11):1711-1716.
[51] LI XH, GAO CJ, DA WM, et al. Reduced intensity conditioning, combined transplantation of haploidentical hematopoietic stem cells and mesenchymal stem cells in patients with severe aplastic anemia. PLoS One. 2014;9(3):e89666.
[52] GAO L, LI Y, ZHANG Y, et al. Long-term outcome of HLA-haploidentical hematopoietic SCT without in vitro T-cell depletion for adult severe aplastic anemia after modified conditioning and supportive therapy. Bone Marrow Transplant. 2014;49(4):519-524.
[53] YAMEI W, RONGMU L, YONGBIN C, et al. Improved outcome of haploidentical transplantation in severe aplastic anemia using reduced-intensity fludarabine-based conditioning. Oncotarget. 2017;8(48):83817-83830.
[54] DEZERN AE, ZAHURAK M, SYMONS H, et al. Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2017;23(3):498-504.
[55] XU LP, JIN S, WANG SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25.
[56] 王丽,吴亚妹,曹永彬,等.单倍体相合造血干细胞移植治疗重型再生障碍性贫血进展[J].解放军医学院学报,2017,38(3):274-276.
[57] 任娟,赵娟,王晓宁.脐血间充质干细胞联合单倍体造血干细胞移植治疗再生障碍性贫血[J].中国组织工程研究, 2018,22(33): 5297-5302.
[58] 郑晓丽,韩冬梅,丁丽,等.单倍体相合造血干细胞移植联合脐带间充质干细胞输注治疗重型再生障碍性贫血并活动性感染的疗效及安全性分析[J].临床血液学杂志,2019,32(3):367-370.
[59] 井远方,卢伟,唐湘凤.单倍体相合造血干细胞移植联合脐带间充质干细胞输注治疗儿童重型再生障碍性贫血的临床观察及安全性分析[J].中华细胞与干细胞杂志(电子版),2018,8(2):111-114.
[60] 冯术青,高峰,朱梦波,等.亲缘单倍体相合外周血造血干细胞移植治疗重症再生障碍性贫血[J].中华移植杂志(电子版), 2011,5(4): 282-285.
[61] 危薇,丁丽,郑晓丽,等.移植物成分对单倍体相合造血干细胞移植治疗再生障碍性贫血后急性移植物抗宿主病的影响[J].中国实验血液学杂志,2018,26(5):1442-1446.
[62] YI T, CHEN Y, WANG L, et al. Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood. 2009;114(14):3101-3112.
|